Patients struggle to access effective weight loss medications due to supply constraints and high costs

People with obesity and metabolic disorders face critical barriers to GLP-1 medications: extreme scarcity of existing drugs (Ozempic, Wegovy), astronomical out-of-pocket costs ($900-1,500/month), and long waitlists. Current solutions are either unavailable or financially inaccessible, forcing patients to delay treatment while pharmaceutical companies race to develop alternatives, creating a desperate market willing to pay premium prices for any viable option.